{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:56Z","timestamp":1788474776512,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jcf.2020.12.006","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T17:22:24Z","timestamp":1608830544000},"page":"499-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor\/ivacaftor trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-3646","authenticated-orcid":false,"given":"John","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-7359","authenticated-orcid":false,"given":"Xiaojun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Kotsimbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2020.12.006_bib0001","doi-asserted-by":"crossref","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcf.2020.12.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/354526a0","article-title":"Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation","volume":"354","author":"Dalemans","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2020.12.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2020.12.006_bib0004","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcf.2020.12.006_bib0005","unstructured":"Cystic Fibrosis Foundation. The clinical and functional translation of CFTR (CFTR2). 2018. https:\/\/cftr2.org\/. Accessed December 18, 2020."},{"key":"10.1016\/j.jcf.2020.12.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jcf.2020.12.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2020.12.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2011.11.024","article-title":"Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function","volume":"148","author":"Rabeh","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2020.12.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1249\/01.MSS.0000150065.97657.7B","article-title":"Oxygen uptake kinetics are slowed in cystic fibrosis","volume":"37","author":"Hebestreit","year":"2005","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jcf.2020.12.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.05.00011404","article-title":"Symptoms, lactate and exercise limitation at peak cycle ergometry in adults with cystic fibrosis","volume":"25","author":"Moorcroft","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2020.12.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1113\/EP085037","article-title":"Skeletal muscle oxidative capacity in patients with cystic fibrosis","volume":"100","author":"Erickson","year":"2015","journal-title":"Exp Physiol"},{"key":"10.1016\/j.jcf.2020.12.006_bib0012","article-title":"American College of Chest Physicians. ATS\/ACCP statement on cardiopulmonary exercise testing","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199212173272504","article-title":"The prognostic value of exercise testing in patients with cystic fibrosis","volume":"327","author":"Nixon","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/thx.52.3.291","article-title":"Exercise testing and prognosis in adult cystic fibrosis","volume":"52","author":"Moorcroft","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2020.12.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201806-1110OC","article-title":"Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis","volume":"199","author":"Hebestreit","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2020.12.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jcf.2020.12.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/PEP.0000000000000086","article-title":"The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective","volume":"26","author":"Saynor","year":"2014","journal-title":"Pediatr Phys Ther"},{"key":"10.1016\/j.jcf.2020.12.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2014.10.019","article-title":"Physiological mechanisms of dyspnea relief following ivacaftor in cystic fibrosis: a case report","volume":"205","author":"Quon","year":"2015","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.jcf.2020.12.006_bib0022","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2020.12.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0024","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"suppl 1","key":"10.1016\/j.jcf.2020.12.006_bib0025","article-title":"Lumacaftor\/ivacaftor (LUM\/IVA) treatment in patients (pts) with cystic fibrosis (CF) aged \u226512 years homozygous for F508del-CFTR: description of a French Temporary Authorization for Use (ATU) cohort","volume":"16","author":"Chiron","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.12.006_bib0026","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1513\/AnnalsATS.201701-058OC","article-title":"An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on Lumacaftor\/Ivacaftor","volume":"14","author":"Jennings","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2020.12.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/adc.46.246.144","article-title":"Pulmonary function and response to exercise in cystic fibrosis","volume":"46","author":"Godfrey","year":"1971","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2020.12.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1249\/00005768-199306000-00007","article-title":"Does peak VO2 reflect VO2max in children?: evidence from supramaximal testing","volume":"25","author":"Rowland","year":"1993","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jcf.2020.12.006_bib0030","first-page":"E6","article-title":"Pediatric exercise testing: value and implications of peak oxygen uptake","volume":"4","author":"Pianosi","year":"2017","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jcf.2020.12.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1159\/000439057","article-title":"Statement on exercise testing in cystic fibrosis","volume":"90","author":"Hebestreit","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.jcf.2020.12.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.201707-570OC","article-title":"CFTR genotype and maximal exercise capacity in cystic fibrosis: a cross-sectional study","volume":"15","author":"Radtke","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2020.12.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2019.03.001","article-title":"Effects of lumacaftor\/ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis","volume":"18","author":"Savi","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.12.006_bib0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12890-019-0866-y","article-title":"Lumacaftor\/ ivacaftor improves exercise tolerance in patients with cystic fibrosis and severe airflow obstruction","volume":"19","author":"Wark","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2020.12.006_bib0035","article-title":"Impact of lumacaftor-ivacaftor on body composition in adults with severe cystic fibrosis lung disease","volume":"52","author":"King","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2020.12.006_bib0036","article-title":"Patterns of change in body composition on treatment with lumacaftor-ivacaftor in severe cystic fibrosis lung disease: early gains in weight and fat mass plateau by one year","volume":"53","author":"King","year":"2018","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320309383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320309383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:43:17Z","timestamp":1761601397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320309383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1569199320309383"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.12.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor\/ivacaftor trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}